Search
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.
Fosphenytoin
go.drugbank.com/drugs/DB01320ApprovedInvestigationalFosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. … Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Uridine triacetate
go.drugbank.com/drugs/DB09144ApprovedIt is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself. … It can also be used as a rescue therapy if severe side effects present within 96 hours after initiation of therapy.
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigationalCisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597].
Products: Nimbex 10mg/ml, Nimbex Injection 2 mg/mlDichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269Approved[L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[L2931] It is administered orally as the salt form avatrombopag maleate. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalCenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. … It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234439] Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival.
Trimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigational[A7688,L33020] However, evidence for this mechanism is controversial.[A233215] Trimetazidine is not FDA approved. However, it has been approved in France since 1978.[L33020] … Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.
Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15710ApprovedWithdrawnthat it was previously exposed to. … The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.
Mixtures: Fluarix Tetra Injektionssuspension in einer Fertigspritze